MedCAC panel has limited confidence that there is enough evidence to show beta amyloid positron emission tomography imaging of the brain changes health outcomes. The vote does not bode well for the technology’s coverage proposal due in July.
A Medicare advisory panel could not find adequate evidence to conclude that beta amyloid positron emission tomography imaging of brain beta amyloid changes health outcomes in patients who display early symptoms or signs of cognitive dysfunction.
CMS convened the Medicare Evidence Development and Coverage Advisory Committee at its Baltimore headquarters on Jan. 30 to review the...
Fresh off an IPO, spinal implant maker Carlsmed is preparing to launch a new cervical fusion application for its aprevo tech. Medtech Insight has two perspectives on these recent moves: CEO Mike Cordonnier and the doctor who performed the first spinal fusion using the technology.
Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.
BD raised its adjusted earnings per share guidance midpoint by $0.18 to a range of $14.30 to $14.45, representing growth of about 9.4% at the midpoint – an increase of approximately 1.4% over prior guidance.
